Skip to main content
Clinical Trials/ITMCTR2000003652
ITMCTR2000003652
Not yet recruiting
Phase 1

A multicenter, randomized, controlled trial for a novel vaginal microecologic therapy for the treatment of persistent cervical human papillomavirus infection at high risk

Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine0 sitesTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
Female

Investigators

Sponsor
Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine

Eligibility Criteria

Inclusion Criteria

  • 1\. Between the ages of 18 and 55, married or sexually active women;
  • 2\. Had been infected with HPV virus for more than one year
  • 3\. After sampling and examination in our hospital, the classification reported the presence of cervical HPV infection, and the syndrome differentiation of TRADITIONAL Chinese medicine belongs to the type of dampness and heat
  • 4\. signed the informed consent.

Exclusion Criteria

  • (1\) Liquid base thin layer cytological examination (TCT) of highly squamous intraepithelial lesions and infiltrating carcinoma, or histopathological examination of CINII and above high\-grade lesions;
  • (2\) Vaginal infections during the week prior to enrollment;
  • (3\) Those who were using other drugs to treat HPV infection or immunosuppressive drugs in the first three months before inclusion;
  • (4\) Women during pregnancy and lactation;
  • (5\) people who have mental diseases or diseases of important organs or metabolic diseases of the body;
  • (6\) Persons with infectious diseases, such as tuberculosis, hepatitis B, or venereal diseases;
  • (7\) For bad life habits or recent exposure to toxic substances, such as drugs, X\-rays;
  • (8\) Therefore, other clinical trial investigators are being accepted.

Outcomes

Primary Outcomes

Not specified

Similar Trials